Unknown PHASE2 INTERVENTIONAL 2-arm NCT03910712

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer

Sponsor: Peking Union Medical College Hospital

Conditions Breast Cancer Female Breast Diseases HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Hormone Receptor Positive Tumor Metastatic Breast Cancer

Interventions Aromatase inhibitor Pyrotinib Trastuzumab

Updated 5 times since 2019 Last updated: Apr 9, 2019 Started: Jun 1, 2019 Primary completion: Jun 1, 2022 Completion: Dec 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03910712, this PHASE2 trial focuses on Breast Cancer Female and Breast Diseases and remains ongoing. Sponsored by Peking Union Medical College Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jan 2024 [monthly]

Not Yet Recruiting PHASE2
May 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking Union Medical College Hospital

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.